DUBLIN – Johnson & Johnson is beefing up its immunology pipeline – and its capabilities in developing bispecific antibodies – by acquiring Covagen AG. Financial terms were not disclosed, but, given Covagen's recent success at attracting finance, the up-front value of the deal should be comfortably north of CHF200 million (US$218 million).